Various diseases are associated with obesity and metabolism. We sought to investigate the risk of cardiovascular disease (CVD) in diverse metabolic obesity phenotypes.
Methods and Results:
A prospective observational study of 1517 participants ≥25 years of age without CVD at baseline was conducted. Participants were categorized into four groups based on the condition of central obesity and metabolic health status: metabolically healthy normal weight, metabolically healthy obesity (MHO), metabolically unhealthy normal weight, and metabolically unhealthy obese (MUO). A multivariate Cox regression analysis was used to analyze the relationship between different obesity phenotypes and CVD. During 14830.49 person-years of follow-up, there were 244 incident cases of CVD. Of the 1517 participants, 72 (4.75%) and 812 (53.53%) were classified as having MHO and MUO, respectively. MHO and MUO had a tendency toward a higher risk of CVD [adjusted hazard ratios (HRs) = 1.49, 95% confidence interval (CI): 1.11–2.02 and HR = 1.25, 95% CI: 1.00–1.55, respectively] based on the waist circumference criterion.
Conclusion:
MHO and MUO can increase the risk of CVD.
Get full access to this article
View all access options for this article.
References
1.
HorwichTB, FonarowGC, ClarkAL. Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis, 2018; 61(2):151–156; doi: 10.1016/j.pcad.2018.05.005
2.
LechiA. The obesity paradox: Is it really a paradox? Hypertension. Eat Weight Disord EWD, 2017; 22(1):43–48; doi: 10.1007/s40519-016-0330-4
3.
Powell-WileyTM, PoirierP, BurkeLE, et al.Obesity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation, 2021; 143(21):e984–e1010; doi: 10.1161/CIR.0000000000000973
4.
Expert Panel onDetection, Evaluation, and Treatment of High Blood Cholesterol inAdults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001; 285(19):2486–2497; doi: 10.1001/jama.285.19.2486
5.
Emerging Risk FactorsCollaboration, WormserD, KaptogeS, et al.Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: Collaborative analysis of 58 prospective studies. Lancet Lond Engl, 2011; 377(9771):1085–1095; doi: 10.1016/S0140-6736(11)60105-0
Romero-CorralA, MontoriVM, SomersVK, et al.Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: A systematic review of cohort studies. Lancet Lond Engl, 2006; 368(9536):666–678; doi: 10.1016/S0140-6736(06)69251-9
8.
LavieCJ, De SchutterA, PatelDA, et al.Body composition and survival in stable coronary heart disease: Impact of lean mass index and body fat in the “obesity paradox.”. J Am Coll Cardiol, 2012; 60(15):1374–1380; doi: 10.1016/j.jacc.2012.05.037
9.
XiaJY, Lloyd-JonesDM, KhanSS. Association of body mass index with mortality in cardiovascular disease: New insights into the obesity paradox from multiple perspectives. Trends Cardiovasc Med, 2019; 29(4):220–225; doi: 10.1016/j.tcm.2018.08.006
10.
LavieCJ, De SchutterA, MilaniRV. Healthy obese versus unhealthy lean: The obesity paradox. Nat Rev Endocrinol, 2015; 11(1):55–62; doi: 10.1038/nrendo.2014.165
11.
AsA, EkO, AntoniadesC, et al.From the BMI paradox to the obesity paradox: The obesity-mortality association in coronary heart disease. Obes Rev Off J Int Assoc Study Obes, 2016; 17(10):989–1000; doi: 10.1111/obr.12440
12.
FerranniniE, NataliA, BellP, et al.Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest, 1997; 100(5):1166–1173; doi: 10.1172/JCI119628
13.
WildmanRP, MuntnerP, ReynoldsK, et al.The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: Prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med, 2008; 168(15):1617–1624; doi: 10.1001/archinte.168.15.1617
14.
LeeK. Metabolically obese but normal weight (MONW) and metabolically healthy but obese (MHO) phenotypes in Koreans: Characteristics and health behaviors. Asia Pac J Clin Nutr, 2009; 18(2):280–284.
15.
RudermanNB, SchneiderSH, BerchtoldP. The “metabolically-obese,” normal-weight individual. Am J Clin Nutr, 1981; 34(8):1617–1621; doi: 10.1093/ajcn/34.8.1617
16.
Gomez-HuelgasR, NarankiewiczD, VillalobosA, et al.Prevalence of metabolically discordant phenotypes in a mediterranean population-The IMAP study. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol, 2013; 19(5):758–768; doi: 10.4158/EP12355.OR
17.
YangC, LiuX, LiJ, et al.Association of serum vitamin D and estradiol levels with metabolic syndrome in rural women of Northwest China: A cross-sectional study. Metab Syndr Relat Disord, 2022; 20(3):182–189; doi: 10.1089/met.2021.0120
18.
BrenemanCB, TuckerL. Dietary fibre consumption and insulin resistance—The role of body fat and physical activity. Br J Nutr, 2013; 110(2):375–383; doi: 10.1017/S0007114512004953
19.
LiH, HeD, ZhengD, et al.Metabolically healthy obese phenotype and risk of cardiovascular disease: Results from the China Health and Retirement Longitudinal Study. Arch Gerontol Geriatr, 2019; 82:1–7; doi: 10.1016/j.archger.2019.01.004
20.
St-PierreAC, CantinB, MauriègeP, et al.Insulin resistance syndrome, body mass index and the risk of ischemic heart disease. CMAJ, 2005; 172(10):1301–1305; doi: 10.1503/cmaj.1040834
21.
MeigsJB, WilsonPWF, FoxCS, et al.Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab, 2006; 91(8):2906–2912; doi: 10.1210/jc.2006-0594
22.
KatzmarzykPT, ChurchTS, JanssenI, et al.Metabolic syndrome, obesity, and mortality: Impact of cardiorespiratory fitness. Diabetes Care, 2005; 28(2):391–397; doi: 10.2337/diacare.28.2.391
23.
ArnlövJ, IngelssonE, SundströmJ, LindL. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation, 2010; 121(2):230–236.
24.
VecchiéA, DallegriF, CarboneF, et al.Obesity phenotypes and their paradoxical association with cardiovascular diseases. Eur J Intern Med, 2018; 48:6–17; doi: 10.1016/j.ejim.2017.10.020
25.
LiuJT, YaoHY, YuSC, et al.Joint Association of Metabolic Health and Obesity with Ten-Year Risk of Cardiovascular Disease among Chinese Adults. Biomed Environ Sci, 2022; 35(1):13–21; doi: 10.3967/bes2022.003
26.
KarelisAD, FarajM, BastardJ-P, et al.The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab, 2005; 90(7):4145–4150; doi: 10.1210/jc.2005-0482
27.
ItohH, KanekoH, KiriyamaH, et al.Metabolically healthy obesity and the risk of cardiovascular disease in the general population—Analysis of a nationwide epidemiological database. Circ J Off J Jpn Circ Soc, 2021; 85(6):914–920; doi: 10.1253/circj.CJ-20-1040
28.
AdairKE, PadgettRN, von WaadenN, et al.Metabolic Health, Obesity, and Cardiovascular Disease: 2015-2016 National Health and Nutrition Examination Survey. Am J Med Sci, 2021; 361(2):244–252; doi: 10.1016/j.amjms.2020.09.010
29.
FanJ, SongY, ChenY, et al.Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: A meta-analysis of prospective cohort studies. Int J Cardiol, 2013; 168(5):4761–4768; doi: 10.1016/j.ijcard.2013.07.230
30.
ChoYK, KangYM, YooJH, et al.Implications of the dynamic nature of metabolic health status and obesity on risk of incident cardiovascular events and mortality: A nationwide population-based cohort study. Metabolism, 2019; 97:50–56; doi: 10.1016/j.metabol.2019.05.002
31.
TianS, LiuY, FengA, et al.Metabolically healthy obesity and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: A protocol for a systematic review and meta-analysis of prospective studies. BMJ Open, 2019; 9(10):e032742; doi: 10.1136/bmjopen-2019-032742
32.
ChoH-W, ChungW, MoonS, et al.Effect of Sarcopenia and Body Shape on Cardiovascular Disease According to Obesity Phenotypes. Diabetes Metab J, 2021; 45(2):209–218; doi: 10.4093/dmj.2019.0223
33.
DahlmanI, ArnerP. Obesity and polymorphisms in genes regulating human adipose tissue. Int J Obes 2005, 2007; 31(11):1629–1641; doi: 10.1038/sj.ijo.0803657
34.
PoriesWJ, DohmLG, MansfieldCJ. Beyond the BMI: The search for better guidelines for bariatric surgery. Obes Silver Spring Md, 2010; 18(5):865–871; doi: 10.1038/oby.2010.8
35.
KatulandaP, WaniganayakeYC, RanasingheP, et al.Retinopathy among young adults with Diabetes Mellitus from a tertiary care setting in Sri Lanka. BMC Endocr Disord, 2014; 14:20; doi: 10.1186/1472-6823-14-20
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
